The prescription THC label: it can worsen mania, depression or schizophrenia, and prescribers are told to screen first
Marinol is synthetic THC, approved for AIDS weight loss and chemotherapy nausea. Its label warns dronabinol "has been reported to exacerbate mania, depression, or schizophrenia" and says to avoid it with a psychiatric history.
Reasonable evidence with real limitations. how we score evidence
Caveat on this rating: Reported effects in label language with no frequencies; applies to synthetic dronabinol at prescribed doses, not directly to plant cannabis.
The FDA-approved label for the one THC product on the US market, read for what it says about mental health.
Significant findings
MARINOL (dronabinol capsules) is indicated in adults for "anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS)" and for "nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments." It has no psychiatric indication.
Warnings and Precautions 5.1, Neuropsychiatric Adverse Reactions: "Dronabinol has been reported to exacerbate mania, depression, or schizophrenia. Significant CNS symptoms followed oral doses of 0.4 mg/kg (28 mg per 70 kg patient) of MARINOL in antiemetic studies. Prior to initiating treatment with MARINOL, screen patients for a history of these illnesses. Avoid use in patients with a psychiatric history or, if the drug cannot be avoided, monitor patients for new or worsening psychiatric symptoms during treatment." The same section warns of cognitive impairment, says elderly patients "may be more sensitive", and tells patients not to drive until they know how it affects them.
Section 9 lists it as a Schedule III controlled substance and describes withdrawal after high doses: irritability, insomnia and restlessness within 12 hours, then hot flashes, sweating, rhinorrhea, loose stools, hiccoughs and anorexia, with "disturbed sleep for several weeks" after stopping high doses.
The other direction
The label also reports that in an open-label study of AIDS patients taking it for up to five months, "no abuse, diversion or systematic change in personality or social functioning were observed". The 0.4 mg/kg dose that produced significant CNS symptoms is well above the usual starting doses. A label lists risks reported for this product; it does not say how often they occur in ordinary use or apply them directly to smoked or edible cannabis.
What this does not show
It does not show THC treats anxiety, sleep or depression; that is not an approved use. It is not a reason to stop a prescribed medication; changes go through the prescriber.
Worth asking
If I use cannabis and have a history of mania, depression or psychosis, does my prescriber know?
Source
MARINOL (dronabinol) capsules: FDA-approved prescribing information, Indications 1, Warnings and Precautions 5.1, Drug Abuse and Dependence 9 — ThePharmaNetwork, LLC; US Food and Drug Administration (2023)
Regulator or national health body
How this was scored
- Study design
- Regulatory safety determination
- Funding
- Industry funded
- Published in
- Regulator or national health body
- Sample size
- not recorded
- Preregistered
- not recorded
- Conflicts disclosed
- not recorded
- Independent of proponent
- not recorded
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published October 21, 2026.
Questions
How strong is the evidence behind this?
veisund rates this source "moderate evidence". Reasonable evidence with real limitations. It scores 57 out of 100 on our published rubric. One caveat travels with that badge: Reported effects in label language with no frequencies; applies to synthetic dronabinol at prescribed doses, not directly to plant cannabis. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
MARINOL (dronabinol) capsules: FDA-approved prescribing information, Indications 1, Warnings and Precautions 5.1, Drug Abuse and Dependence 9 — ThePharmaNetwork, LLC; US Food and Drug Administration (2023). Published in: Regulator or national health body. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Regulatory safety determination. Funding: Industry funded. Independence from the proponent is not recorded. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is cannabis-thc, marijuana, weed, thc, delta-9-tetrahydrocannabinol, medical cannabis, dronabinol, marinol FDA approved?
Yes — this medication carries FDA approval. Approval is always for a specific indication, not for every use it is prescribed for.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.